Gynica

20/08/2022

The leading israeli lifestyle magazine, מגזין את ATmag , featured some of the innovations presented at the WHII - Women's Health Innovations and Inventions conference in Tel Aviv, including Gynica's cannabinoids-based solutions.

***

10/08/2022

first! At Gynica Healthcare we are committed to medically meeting the unmet needs of women’s health (or, half the world’s population). Thank you Na'ama Barak and ISRAEL21c for shining the limelight on this mission in an interview with our Founder & CEO Yotam Hod, discussing femtech , market and .

“Most that I meet are men, and there are stigmas and taboos surrounding issues that haven’t traditionally been put out there. Bleeding, menstruation, s*x – these are topics that are taboo, and which are often addressed with a half-smile. That’s a paradigm that has to change. Every male investor has a wife, a mother or a sister, but they’re still not always aware of the difficulties that they encounter,” Yotam explains.

After years of neglect, this fledgling high-tech sector is addressing the modest issue of meeting the needs of half the world’s population.

05/07/2022

Join the Gynica Healthcare session at WHII 2022!

On July 12, from 10:00 to 11:45 our team will be hosting a 1-hour discussion on Revolutionizing the medical cannabis industry while addressing Unmet Needs in Women’s Health. Chaired by Felice Petraglia and Prof Moshe Hod the session will include leading experts in pharma, women's health, VC funding, and medical cannabis.

The Gynica session is a part of the Women's Health Inventions and Innovations Congress 2022 that will be held at The Hilton Tel Aviv on July 11-12, Chaired by Gynica's Chairman Prof Moshe Hod.

To secure your seats and get more information about the session and the conference visit https://lnkd.in/e3himed

07/06/2022

Breaking news – Gynica is entering the menopause space!

We are thrilled to be recognized by Calcalist כלכליסט as one of the innovative Israeli companies taking innovation to women’s health to address women’s menopause-related health issues that severely impact their quality of life.

About 1.2 billion women (a seventh of the world's population) are suffering from a range of medical symptoms related to one of the stages of menopause such as hot flashes, joint and muscle pain, nervousness, anxiety, depression, severe sleep disorders, calcium leakage, pelvic prolapse, dryness and vaginal burning, pain during in*******se, and difficulty in memory and concentration – according to a McKinsey & Company report.

The menopause market was already worth $15 billion annually in 2020 and it’s expected to grow by 6% every year, according to Grand View Research. However, menopause has not received merely enough attention from the medical and research community, and women are paying the price.

We are changing that now, introducing cannabis innovation into the menopause market!

Led by our VP of R&D Dr. Sari Prutchi Sagiv, Gynica began last year to develop the GYN501 solution which caters to the physical and mental needs of women going through menopause. "The female reproductive system is the organ with the most cannabis receptors in the human body after the brain, so the therapeutic potential is huge", she says. “Both cannabis and women's health are taboos that have been stigmatized for years and years, so I have been working to break these stigmas”, says our Co-Founder and CEO Yotam Hod

Read the full story (Hebrew): https://lnkd.in/dRnQufDt

02/05/2022

We are celebrating a special honor!

Congratulations to our President and Chairman of the Board Prof. Moshe Hod for receiving a Lifetime Achievement Award from the Israel Society of Obstetrics & Gynecology.

Prof. Hod is a world-renowned expert in gynecology, senior lecturer in obstetrics and gynecology at Tel Aviv University's Faculty of Medicine, serves as Head of the Mor Institute for Women's Health in Tel Aviv, Member and former Chair of the Federation of Obstetrics and Gynecology (FIGO)'s board, and former President of the European Association of Perinatal Medicine (EAPM).

He received this award for his life's work and contribution to the field of gynecology in particular. At Gynica, Prof. Hod focuses on clinical research for cannabis-based vaginal products to treat gynecological problems for which no effective medical solution has been found to date and on research and development of drugs for gynecological conditions.

04/04/2022

We are honored to have been invited to speak at the conference in Bangkok, and delighted to meet with Israeli Ambassador Ms Orna Sagiv, learning about her important project in !

Global investments in women’s health companies are on the rise, boosting in women’s health as a stand-alone field that requires case-specific solutions.
We were happy to receive genuine interest in Bangkok for Gynica Healthcare’s local approach to treating women’s medical conditions effectively with based clinical products, avoiding any impact on other systems in the woman’s body.

23/03/2022

Thank you University of Oxford for the generous invitation to present at the 2022 conference focused on women’s health!

We couldn’t be prouder of our visionary Co-Founder & CEO Yotam Hod and our amazing VP R&D Dr Sari Prutchi Sagiv as they showcased Gynica's groundbreaking Cannabinoids-based femtech products yesterday, attracting genuine interest from opinion leaders in the pharma industry and the academy.

"Gynica was invited as part of 12 companies to discuss the challenges behind our innovative cannabinoid-based pharmaceutical products”, said Mr. Hod. “We were delighted for the opportunity to take part in such an inspiring interdisciplinary discourse on how to treat medical conditions in women’s health with a more effective and local approach, helping to improve women’s quality of life”.

Dr Sagiv said: “In the face of the growing awareness in the world for the need to innovate in women’s health, it is crucial to create these collaborations between industry and academia. Reviewing the research questions and development issues from the industry will enable us to find new solutions to existing challenges”, she added.

We applaud the wonderful women leading the change in women’s healthcare: Prof Krina Zondervan - Head of the Nuffield Department of Women´s and Reproductive Health at the University of Oxford for your active support in finding new practical solutions to address the challenges in women’s health; Emma Tegala - Head of Resources at Endometriosis UK for bringing forward the gaps in response to this widespread condition; Dr Nicole Schmidt - Head of Reproductive Health at Bayer for promoting interdisciplinary industry/academy partnerships throughout the world. Your support is priceless!

And, special thanks go out to Denitsa Filipova from Oxford University for inviting us.

28/12/2021

Gynica is thrilled to be featured on Geektime גיקטיים, the largest tech media platform in Israel.

The first-ever clinical trial dealing with cannabis-based vaginal products that treat gynecological problems has just completed a round of preclinical studies.

26/12/2021

Our very own Dr. Sari Prutchi Sagiv presenting Gynica's research & vision on i24 News.

20/12/2021

is booming, as you can see in Femtech Analytics' 2021 report.
Look up for Gynica

FemTech Industry Landscape Overview Q4 2021 summarizes vital observations in the FemTech ecosystem, a rapidly evolving and growing industry. Based on the assembled and analyzed data, the report reveals vital features, trends, innovations, technologies, market size, among other perspectives.

13/11/2021

Gynica is honored to be chosen to participate in the first program of Station F - the world's biggest startup campus.

These are exciting times for women's health & s*xual wellness!

12/09/2021

Dr. Sari Prutchi Sagiv, Gynica's VP R&D, had the great privilege to present our work (in Spanish!) on women's health & the endocannabinoid system, to 60 doctors and medical professionals participating in the Diploma of Advanced Studies in Endocannabinology, Cannabis & Cannabinoids, at The National University of Rosario (UNR), Santa Fe, Argentina.

Thank you Dr. Raquel Peyraube for inviting us and for promoting the future of Endocannabinology education.